Quarterly ResultJul 27, 2026, 07:56 AM
AstraZeneca H1 Revenue +6% to $30.67B; Core EPS +11% to $5.21
AI Summary
AstraZeneca PLC reported strong H1 2026 results with Total Revenue up 6% CER to $30.67 billion and Core EPS up 11% CER to $5.21. Q2 2026 also showed robust growth, with Total Revenue increasing 5% CER to $15.38 billion and Core EPS rising 18% CER to $2.63. The company reconfirmed its FY 2026 guidance for mid-to-high single-digit Total Revenue growth and low double-digit Core EPS growth at constant exchange rates. AstraZeneca also announced two significant licensing agreements, including a $600 million upfront payment for Zegfrovy from Dizal Pharmaceutical and a $200 million upfront payment for TQC3721 from Sino Biopharmaceutical, while acknowledging some pipeline setbacks.
Key Highlights
- H1 2026 Total Revenue increased 6% CER to $30.67 billion.
- H1 2026 Core EPS grew 11% CER to $5.21.
- Q2 2026 Total Revenue increased 5% CER to $15.38 billion.
- Q2 2026 Core EPS grew 18% CER to $2.63.
- Interim dividend increased by 3 cents to $1.06 per share.
- Acquired worldwide rights to Zegfrovy from Dizal for $600M upfront, up to $900M milestones.
- Licensed TQC3721 from Sino Biopharmaceutical for $200M upfront, up to $1.9B milestones.
- Reconfirmed FY 2026 guidance for mid-to-high single-digit Total Revenue growth.
Price Impact
More from AZN